Provided by Tiger Trade Technology Pte. Ltd.

Vor Biopharma Inc.

22.34
-0.8950-3.85%
Post-market: 22.340.00000.00%16:15 EDT
Volume:686.88K
Turnover:15.45M
Market Cap:1.32B
PE:1.94
High:23.09
Open:22.96
Low:22.09
Close:23.24
52wk High:49.95
52wk Low:6.50
Shares:59.16M
Float Shares:37.23M
Volume Ratio:0.99
T/O Rate:1.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):11.53
EPS(LYR):-70.5015
ROE:-125.43%
ROA:-21.37%
PB:-6.60
PE(LYR):-0.32

Loading ...

Major Insider Shake-Up at Vor Biopharma as Key Stakeholder Trims Position

TIPRANKS
·
Apr 16

RA Capital Management disposes Vor Biopharma common shares worth $11.9 million

Reuters
·
Apr 16

Vor Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 15

Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up

TIPRANKS
·
Apr 11

Major Insider Move Shakes Up Vor Biopharma Trading Activity

TIPRANKS
·
Apr 11

RA Capital Healthcare Fund disposes Vor Biopharma shares worth $10.3 million

Reuters
·
Apr 11

Vor Biopharma files Form 3 for new Chief Medical Officer Jeremy Brett Sokolove

Reuters
·
Apr 10

Major Insider Move Rocks Vor Biopharma as Director Unloads Massive Stake

TIPRANKS
·
Apr 07

RA Capital Management disposes of Vor Biopharma common shares worth $14.6 million

Reuters
·
Apr 07

BRIEF-Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 02

Vor Biopharma initial beneficial ownership filed by TCG Crossover GP II, LLC

Reuters
·
Apr 02

Vor Bio grants inducement equity awards to 9 new hires under Nasdaq rule

Reuters
·
Apr 02

Vor Biopharma Is Maintained at Neutral by Wedbush

Dow Jones
·
Mar 31

Vor Bio price target raised to $15 from $9 at Wedbush

TIPRANKS
·
Mar 31

Vor Biopharma: Solid Clinical Execution and Strengthened Balance Sheet Support Buy Rating and Long-Term Growth Outlook

TIPRANKS
·
Mar 30

Vor Biopharma Q4 Adj. EPS $(1.63) Beats $(1.64) Estimate

Benzinga Earnings
·
Mar 30

Vor Biopharma Initiated at Buy by Jefferies

Dow Jones
·
Mar 30

Vor Biopharma Q4 profit tops estimates on warrant fair value gain

Reuters
·
Mar 30

Vor Bio Q4 FY25 net income climbs to $1.7B; pro-forma cash rises to $530M

Reuters
·
Mar 30

Vor Bio doses first patient in Phase 3 telitacicept Sjögren’s disease trial

Reuters
·
Mar 30